Novo Nordisk’s stock fell after semaglutide’s Alzheimer’s news. Click here for how strong fundamentals and growth catalysts make NVO a compelling long-term Hold.
Novo Nordisk Hits A 10-Year Low – I Think The Market Is Making A Mistake
view original post